The efficacy of combined oral therapy with efrotomycin and bottromycin in Bordetella bronchiseptica infections has been studied by administration of a constant concentration of one drug while varying the concentration of the other drug.
Data from experiments in which bottromycin was held constant in combination with different concentrations of efrotomycin are summarized in Table 2 . Both concentrations of bottromycin in combination with varied doses of efrotomycin gave a marked reduction in the amount of efrotomycin required for 50% protection (ED50). The results of experiments in which fixed concentrations of efrotomycin were combined with different concentrations of bottromycin are summarized in Table 3 . We were unable to determine the ED50 for bottromycin alone because of the lack of pure drug. However, with the impure sample available for testing, it seems probable that the ED50 is considerably greater than two oral doses of 20 mg per mouse. This dosage level cannot be considered toxic as it was well tolerated by mice which received oral doses of efrotomycin.
Bottromycin alone gave an erratic dose response in the first experiment and did not protect any of the infected mice in the second trial even though the challenge infections in both tests were approximately the same. However, in both tests combination of bottromycin with l mg doses of efrotomycin resulted in many more survivors than with bottromycin alone.
The data in Table 3 support the in vivo synergy of efrotomycin and bottromycin. Insufficient supply of bottromycin prevented further in vivo trials with B. bronchiseptica or other infections. The best explanation for the observed synergy of efrotomycin and bottromycin is that they act at close metabolic sites.
At the beginning of this study, the mode of action of kirromycin was known". This agent inhibits peptide bond formation by acting on elongation factor (EF-Tu)8. Efrotomycin, which is closely related structurally to kirromycin9), since has been found to inhibit EF-Tu dependent reactions10). Bottromycins are a group of closely related antibiotics11).
One of these, bottromycin A2, was reported prior to this study to be an inhibitor of protein synthesis12).
The antibiotic also was shown to inhibit translocation of peptidyl-tRNA by interacting with the large ribosomal subunit13,14 
